Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors. For additional information, please visit Kura’s website at www.kuraoncology.com.

Hercules Capital

Bristol-Myers Squibb

Cowen Investment Management

Deerfield Management

EcoR1 Capital

Suvretta Capital Management

ARCH Venture Partners

Nextech Invest

OUP (Osage University Partners)

Fidelity Management and Research Company

Tavistock Life Sciences

Partner Fund Management

Kura Oncology, Inc.

A clinical-stage biopharmaceutical company focused on developing highly selective kinase inhibitors for genomically defined cancers.

Blueprint Medicines Corporation

A clinical-stage targeted oncology company developing novel therapeutics for the treatment of cancer.

Mirati Therapeutics, Inc.

A biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer.

Deciphera Pharmaceuticals, Inc.

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company's pipeline includes small molecule product candidates targeting genetically defined subsets of acute leukemias and solid tumors.

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 2, 2024 12:48 AM	ef619a04
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 2, 2024 12:48 AM	ddf7a0a8
company summary	general
signals	general
crunchbase trigger	general	Nov 12, 2024 12:52 PM	606cbd6b
crunchbase profile	general
li profile	general	Mar 2, 2024 12:48 AM	29f084ef
translate crunchbase fundingrounds	general
peers	general
news basic	general	Mar 2, 2024 12:48 AM	5d3cc8eb
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:KURAONCOLOGY

Kura Oncology, Inc.

Last Close

10.06

22/11 21:00

Market Cap

822.75M

Beta: -

Volume Today

6.87M

Avg: -